Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Matched Targeted Therapy”

57 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 57 results

Not applicableLooking for participantsNCT06626893
What this trial is testing

Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention

Who this might be right for
Myeloid Leukemia, AcuteLeukemia, Acute Lymphoblastic
Azienda Ospedaliero-Universitaria di Parma 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439110
What this trial is testing

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 38
Not applicableActive Not RecruitingNCT02520713
What this trial is testing

The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

Who this might be right for
Pediatric Solid Tumor
Dana-Farber Cancer Institute 825
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439123
What this trial is testing

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT06351371
What this trial is testing

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390865
What this trial is testing

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439136
What this trial is testing

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439344
What this trial is testing

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439357
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 4
Not applicableLooking for participantsNCT06669377
What this trial is testing

TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.

Who this might be right for
Hepatocellular Carcinoma
Zhongda Hospital 444
Early research (Phase 1)Ended earlyNCT00973804
What this trial is testing

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

Who this might be right for
LeukemiaNon-Hodgkins LymphomaHodgkins Lymphoma+2 more
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439279
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439227
What this trial is testing

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 33
Testing effectiveness (Phase 2)Study completedNCT03158389
What this trial is testing

NCT Neuro Master Match - N²M² (NOA-20)

Who this might be right for
Glioblastoma, Adult
University Hospital Heidelberg 228
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439201
What this trial is testing

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+2 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03155620
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+42 more
National Cancer Institute (NCI) 1,377
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Looking for participantsNCT07499271
What this trial is testing

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University 35
Testing effectiveness (Phase 2)UnknownNCT04284228
What this trial is testing

Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
NexImmune Inc. 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390826
What this trial is testing

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 10
Next Page